Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: Results from TARGET (do tirofiban and reopro give similar efficacy trial?)

Catheterization and Cardiovascular Interventions

Volumn 69, Issue 5, 2007, Pages 623-629

  Kalyanasundaram, Arun ^a   Blankenship, James C ^a   Berger, Peter ^a   Herrmann, Howard ^b   McClure, Rick ^c   Moliterno, David ^c  

^a GEISINGER MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Glycoprotein IIb IIIa inhibitors; Percutaneous coronary intervention; Saphenous vein graft; Stents

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ANGIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; Q WAVE; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK ASSESSMENT; SAPHENOUS VEIN GRAFT; STENT; THROMBUS; UNIVARIATE ANALYSIS;

AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREDICTIVE VALUE OF TESTS; REOPERATION; RESEARCH DESIGN; RISK FACTORS; SAPHENOUS VEIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TYROSINE; VENOUS THROMBOSIS;

EID: 34147194449     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20963     Document Type: Article

References (33)

1. Keon WJ, Heggtveit HA, Leduc J. Perioperative myocardial infarction caused by atheroembolism. J Thorac Cardiovasc Surg 1982;84:849-855.
2. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP Jr, Kuntz RE, Bairn DS. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994;89:2514-2518.
3. Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol 1999;33:88-96.
4. Ioannidis JP, Karvouni E, Katritsis DG, et al. Mortality risk conferred by small elevations of creatine kinase - MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1406-1411.
5. Hong MK, Mehran R, Dangas G, et al. Creatine kinase - MB, enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999; 100:2400-2405.
6. Gorog DA, Foale RA, Malik I. Distal myocardial protection during percutaneous coronary intervention: When and where? J Am Coll Cardiol 2005;46:1434-1445.
7. Sievert H, Wahr DW, Schuler G, Schofer JJ, Sutsch G, Pavliska J, Skowasch M. Effectiveness and safety of the Proxis system in demonstrating retrograde coronary blood flow during proximal occlusion and in capturing embolic material. Am J Cardiol 2004; 94:1134-1139.
8. Lim MJ, Young JJ, Senter SR, Klein LW. Determinants of embolic protection device use: Case study in the acceptance of a new medical technology. Catheter Cardiovasc Interv 2005;65: 597-599.
9. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.
10. Valgimigli M, Percoco G, Cicchitelli G, Ferrari F, Barbieri D, Ansani L, Guardigli G, Parrinello G, Malagutti P, Soukhomovskaia O, et al. High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study - Protocol design and demography of the first 100 patients. Cardiovasc Drugs Ther 2004;18:225-230.
11. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The ADVANCE trial. J Am Coll Cardiol 2004;44:14-19.
12. Danzi GB, Capuano C, Sesana M, Baglini R. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement. Catheter Cardiovasc Interv 2004;61:179-184.
13. Singh M, Rosenschein U, Ho KK, Berger PB, Kuntz R, Holmes DR Jr. Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: A randomized study (ATLAS). Circulation 2003;107:2331-2336.
14. Leborgne L, Cheneau E, Pichard A, Ajani A, Pakala R, Yazdi H, Satler L, Kent K, Suddath WO, Pinnow E, et al. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. Am Heart J 2003;146:501-506.
15. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM, Brennan DM, Ellis SG, Topol EJ. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five randomized clinical trials. Circulation 2002;106:3063-3067.
16. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-1290.
17. Mathew V, Grill DE, Scott CG, Grantham JA, Ting HH, Garratt KN, Holmes DR Jr. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. J Am Coll Cardiol 1999;34:1163-1169.
18. Lefkovits J, Holmes DR, Califf RM, Safian RD, Pieper K, Keeler G, Topol EJ. Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Coronary angioplasty versus excisional atherectomy trial. Circulation 1995;92:734-740.
19. Carrozza JP Jr, Mumma M, Breall JA, Fernandez A, Heyman E, Metzger C. Randomized evaluation of the TriActiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease. J Am Coll Cardiol 2005;46:1677-1683.
20. Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Turco M, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003;108:548-553.
21. Stone GW, Rogers C, Ramee S, White C, Kuntz RE, Popma JJ, George J, Almany S, Bailey S. Distal filter protection during saphenous vein graft stenting: Technical and clinical correlates of efficacy. J Am Coll Cardiol 2002;40:1882-1888.
22. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB HI, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Circulation 2006;113:156-175.
23. Mathew V, Lennon RJ, Rihal CS, Bresnahan JF, Holmes DR Jr. Applicability of distal protection for aortocoronary vein graft interventions in clinical practice. Catheter Cardiovasc Interv 2004;63:148-151.
24. Ross MJ, Herrmann HC, Moliterno DJ, Blankenship JC, Demopoulos L, DiBattiste PM, Ellis SG, Ghazzal Z, Martin JL, White J, et al. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: Results from the TARGET trial. J Am Coll Cardiol 2003;42:981-988.
25. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 1994;330:956-961.
26. Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ,EPIC Investigators. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in preventing ischemic complications. Am J Cardiol 1997;80:985-988.
27. Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: The TARGET trial. Circulation 2002; 105:2347-2354.
28. Savage MP, Douglas JS, Jr., Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997;337(11):740-747.
29. Keeley EC, Velez CA, O'Neill WW, Safian RD. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 2001;38(3):659-665.
30. Hong MK, Mehran R, Dangas G, et al. Are we making progress with percutaneous saphenous vein graft treatment? A comparison of 1990 to 1994 and 1995 to 1998 results. J Am Coll Cardiol 2001;38(1):150-154.
31. Giugliano GR, Kuntz RE, Popma JJ, Cutlip DE, Bairn DS. Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol 2005;95:173-177.
32. den Heijer P, Foley DP, Escaned J, Hillege HL, van Dijk RB, Serruys PW, Lie KI. Angioscopic versus angiographic detection of intimal dissection and intracoronary thrombus. J Am Coll Cardiol 1994;24:649-654.
33. Teirstein PS, Schatz RA, DeNardo SJ, Jensen EE, Johnson AD. Angioscopic versus angiographic detection of thrombus during coronary interventional procedures. Am J Cardiol 1995;75: 1083-1087.